Диссертация (1154314), страница 19
Текст из файла (страница 19)
et al. Klotho Deficiency Causes VascularCalcification in Chronic Kidney Disease // J. Am. Soc. Nephrol. – 2011. – Vol.22(1). – P. 124–136. doi: 10.1681/ASN.2009121311PMCID: PMC301404116. Hu M.C., Shiizaki K., Kuro-o M,, Orson W. Moe Fibroblast Growth Factor 23and Klotho: Physiology and Pathophysiology of an Endocrine Network of MineralMetabolism: // Annu. Rev. Physiol. – 2013. – Vol. 75.
– P. 503–533.doi: 10.1146/annurev-physiol-030212-18372717. Hu M. C. , Kuro-o M. , Orson W. Moe. The emerging role of Klotho inclinical nephrology // Nephrol Dial Transplant. - 2012. – Vol. 27(7). – P. 2650–2657. doi: 10.1093/ndt/gfs160.
PMCID:18. Kuro-o M, Matsumura Y, Aizawa H. et al. Mutation of the mouse klotho geneleads to a syndrome resembling ageing // Nature. – 1997. – Vol. 390. – P. 45–51,[PubMed]19. John GB, Cheng CY, Kuro-o M. Role of Klotho in aging, phosphatemetabolism, and CKD // Am J Kidney Dis. – 2011. – Vol. 58: - P. 127–134 [PMCfree article] [PubMed]20. Hu M.C., Kuro-o M., Moe O. W.
Klotho and Chronic Kidney Disease //Contrib Nephrol. – 2013. – Vol. 180. – P. 47–63.21. Urakawa I, Yamazaki Y., Shimada T et al. (2006) Klotho converts canonicalFGF receptor into a specific receptor for FGF23. Nature 444: 770–774 [PubMed]22. Imura A., Iwano A., Tohyama O. et al. Secreted Klotho protein in sera andCSF: implication for post-translational cleavage in release of Klotho protein fromcell membrane // FEBS Lett . – 2004. – Vol. 565. – P. 143–147 [PubMed]23. Chen C.D., Podvin S., Gillespie E.
Insulin stimulates the cleavage and releaseof the extracellular domain of Klotho by ADAM10 and ADAM17 // Proc NatlAcad Sci U S A. -2007. – Vol. 104. – P. 19796–19801 [PMC free article][PubMed]24. Asai O., Nakatani K., Tanaka T. et al. Decreased renal α-Klotho expression inearly diabetic nephropathy in humans and mice and its possible role in urinarycalcium excretion // Kidney Int. 2012. – Vol.
81. – P. 539–547 [PubMed]25. Shimamura Y., Hamada K., Inoue K. et al. Serum levels of soluble secretedalpha-Klotho are decreased in the early stages of chronic kidney disease, making ita probable novel biomarker for early diagnosis // Clin Exp Nephrol. 2012. – Vol.16. – P. 722–729 [PubMed]26. Nagai R., Saito Y., Ohyama Y. et al. Endothelial dysfunction in the klothomouse and downregulation of klotho gene expression in various animal models of124vascular and metabolic diseases // Cell Mol Life Sci.
2000. – Vol. 57. – P. 738–746[PubMed]27. Saito Y., Yamagishi T.., Nakamura T. et al. Klotho protein protects againstendothelial dysfunction. Biochem Biophys Res Commun 248: 324–329 [PubMed]28. Kusaba T, Okigaki M, Matui A et al. (2010) Klotho is associated with VEGFreceptor-2 and the transient receptor potential canonical-1 Ca2+ channel tomaintain endothelial integrity // Proc Natl Acad Sci U S.
- 1998. – Vol. 107. – P.19308–19313 [PMC free article] [PubMed]29. Imura A., Tsuji Y., Murata M. et al. alpha-Klotho as a regulator of calciumhomeostasis. Science. – 2007. – Vol. 316. – P. 1615–1618 [PubMed]30. Kurosu H., Yamamoto M., Clark J.D. et al. Suppression of aging in mice bythe hormone Klotho. Science. – 2005. – Vol.
9. - P. 1829–1833 [PMC free article][PubMed]31. Semba R.D., Cappola A.R., Sun K. et al. Relationship of low plasma klothowith poor grip strength in older community-dwelling adults: the InCHIANTIstudy. Eur J Appl Physiol. - 2012. – Vol. 112. – P. 1215–1220 [PMC free article][PubMed]32. Semba R.D., Cappola A.R., Sun K. et al. Plasma klotho and cardiovasculardisease in adults.
J Am Geriatr Soc.- 2011.- Vol. 59. – P. 1596–1601 [PMC freearticle] [PubMed]33. Semba R.D., Cappola A.R., Sun K. et al. Plasma klotho and mortality risk inolder community-dwelling adults // J Gerontol A Biol Sci Med Sci. – 2011. – Vol.66. – P. 794–800 [PMC free article] [PubMed]34. Devereux R.B. The value of noninvasive measurements in hypertension // J.Am. Med.
Assoc.- 1990. – Vol. 264(2). – P. 279835. Schillaci G., Verdecchia P., Borgioni C., Ciucci A., Guerrieri M., Zampi I.,Battistelli M., Bartoccini C., Porcellati C. Improved electrocardiographic diagnosisof left ventricular hypertrophy // Am J Cardiol. – 1994. – Vol. 74. – P.
714–719.[PubMed]36. Levey A.S., Atkins R., Coresh J. et al. Chronic kidney disease as a globalpublic health problem: approaches and initiatives – a position statement fromKidney Disease Improving Global Outcomes // Kidney Int. – 2007. – Vol. 72 (3).– P. 247–25937. Добронравов В.А., Смирнов А.В, Драгунов С.В. и соавт. Эпидемиологияхронической почечной недостаточности в Северо-Западном регионе России:на пути к созданию регистра хронической почечной недостаточности //Тер.aрхив. – 2004. – Vol. 76(9).
– P. 57-6138. Смирнов А.В., Шилов Е.М., Добронравов В.А. и соавт. Национальныерекомендации ХБП: основные положения, определение, диагностика,скрининг, подходы к профилактике и лечению // Клиническая нефрология. –2012. - N 4. – C. 4-2639.
Ермоленко В.М., Волгина Г.В., Добронравов В.А. и соавт. Национальныерекомендации по минеральным и костным нарушениям при хроническойболезни почек. Российское диализное общество (май 2010) // Нефрология идиализ. – 2011. – Т. 13 (1)ю – С. 33-5112540.Couser W.G., Remuzzi G., Mendis S. et. al. The contribution of chronic kidneydisease to the global burden of major noncommunicable diseases // Kidney int.2011. – Vol.
80(12). – P. 1258-70. 2).41. Lu K-C., Wu. C-C, Yen J-F et al. Vascular calcification and Renal BoneDisorders // Scientific World Journal. – 2014. - Published online 2014. – Vol. 17.doi: 10.1155/2014/637065.3).42. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD WorkGroup. KDIGO clinical practice guideline for the diagnosis, evalution, prevention,and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) //Kidney Int. – 2009.
– Vol. 76 (Suppl.113). – P. 1-130].43. Милованова Л.Ю., Николаев А.Ю., Милованов Ю.С., Савина Л.Н.Хроническая почечная недостаточность – важнейшая и малоизученнаяпричина сердечно-сосудистой смертности // Тер. арх.- 2006. - N 5. – C. 51- 5644. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD WorkingGroup. KDIGO clinical practice guideline for the diagnosis, evolution, prevention,and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) //Kidney Int. - 2009. – Vol. 76(113). - S3-S845.
Wright N.C., Looker A.C., Saag K.G., Curtis J.R., Delzell E.S,. Randall S.,Dawson-Hughes B. The recent prevalence of osteoporosis and low bone mass inthe United States based on bone mineral density at the femoral neck or lumbarspine // J. Bone Miner .Res. – 2014. – Vol. 29(11). – P. 2520–646. Sarnak M.J. Cardiovascular complications in chronic kidney disease // Fm. J.Kidney Dis. – 2003.
– Vol. 41. – P. 11-1747. Anavekar N.S., McMurray J.J., Velazquez E.J. et al. Relation between renaldysfunction and cardiovascular outcomes after myocardial infarction // N. Eng. J.Med. – 2004. – Vol. 351(13). – P. 1285 –129548. Keith D.S., Nicholas G.A., Gullion C.M. et al. Longitudinal follow-up andoutcomes among a population with chronic kidney disease in a large managed careorganization // Arch. Intern. Med.
– 2004. – Vol. 164(6). – P. 659–66349. Coresh J., Selvin E., Stevens L.A. et al. Prevalence of Chronic Kidney Diseasein the United States // JAMA. – 2007 .- V0l. 298(17). – P. 2038-204750. Milovanova L., Milovanov Y., Plotnikova A.
Phosphorus and CalciumMetabolism Disorders Assosiated with Chronic Kidney Disease Stage III-IV(Systematic Rewiew and Meta-Analysis). Chronic Kidney Disease and renalTransplantation // Ed. by Manisha Sahay. INTECH. – 2012. – P. 95-11851. Keith A Hruska., Suresh Mathew., Richard Lund. et al. Hyperphosphatemiaof chronic kidney disease // Kidney Int.
– 2008. – Vol. 74(2). – P. 148-15752. Дзитоева М.Ю., Милованов Ю.С., Шилов Е.М. Кальцификацияпериферических артерий у больных с терминальной почечнойнедостаточностью // Тер. арх. – 2005. – N. 5. – C. 35-3953. Nitta K, Okada K. et al. Aging and chronic kidney disease // Kidney BloodPress Res. – 201.- Vol. 38(1). – P.
109-2054. Милованова Л.Ю., Николаев А.Ю., Милованов Ю.С. Гиперфосфатемиякак фактор риска сердечно-соудистых заболеваний у больных ХПН //Нефрол. и диал. – 2002. – N. 2. – P. 113-117.12655. Foley R., Murray A.M., Li S. et al.
Chronic kidney disease and the risk forcardiovascular disease, renal replacement, and death in the United States medicarepopulation, 1998 to 1999 // J. Am. Soc. Nephrol. – 2005. – Vol. 16(2). – P. 489–49556. Goodman W.G., Goldin J., Kuizon B.D. et al. Coronary-artery calcification inyoung adults with end-stage renal disease who are undergoing dialysis // N. Eng.J. Med.
– 2000. – Vol. 342(20). – P. 1478–148357. Raggi P., Boulay A., Chasan-Taber S. et al. Cardiac calcification in adulthemodialysis patients. A link between end-stage renal disease and cardiovasculardisease? // Am. Coll. Cardiol. – 2002. – Vol. 39(4). – P. 695–7019958.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
